General Information of the Disease (ID: DIS00048)
Name
Adrenocortical carcinoma
ICD
ICD-11: 2D11
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Adrenocortical carcinoma [ICD-11: 2D11]
Responsed Drug Romidepsin Investigative
Responsed Regulator Histone deacetylase 1 (HDAC1) Suppressor
Pathway Response Cell adhesion molecules hsa04514
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SW13 cells Adrenal cortex carcinoma Homo sapiens CVCL_0542
Response regulation HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Adrenocortical carcinoma [ICD-11: 2D11]
Responsed Drug Romidepsin Investigative
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
Pathway Response Cell adhesion molecules hsa04514
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SW13 cells Adrenal cortex carcinoma Homo sapiens CVCL_0542
Response regulation HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis.
References
Ref 1 HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells. Redox Biol. 2021 Nov;47:102149. doi: 10.1016/j.redox.2021.102149. Epub 2021 Sep 25.